| HOME >> BIOLOGY >> TECHNOLOGY |
Tiny electrodes have been coated with a drug-loaded polymer in an attempt to design an implant capable of detecting a number of neurological symptoms, such as those associated with an epileptic seizure, and treating them simultaneously.
In a study published today, 2 June 2011, in IOP Publishing's Journal of Neural Engineering, researchers have developed a novel technology to precisely modulate individual neurons in rats, allowing the molecular, neuronal, and circuit functions to be analysed with unprecedented precision.
Based on the electrical conducting properties of the polymer Polypyrrole (PPy), the researchers, from the University of Pittsburgh, have demonstrated a novel way of loading specific drugs onto an array of electrodes and triggering their release into cultured neurons, allowing for a more precise insight into the cellular mechanisms of neuronal networks.
On top of this, the researchers have also demonstrated how the release of drugs could be informed, in real-time, by the recording of activity in neurons, a step essential for creating a closed-loop system that both diagnoses and treats symptoms simultaneously, creating several potential applications.
Co-author Professor X Tracy Cui said, "We envision an implanted device in the future that will monitor the brain activity, detect or predict an onset of epileptic seizure, and send the command to the electrode at the most appropriate location, releasing an anti-convulsive drug to prevent the seizure."
Multielectrode arrays (MEAs) small devices that can control or record the electrical circuitry in neurons have long been used as a way of measuring neuronal activity and transforming this into an action; technologies such as ear implants and cardiac pacemakers have benefited from them.
Recent advances, however, have allowed MEAs to be coupled with devices that release specific drugs in order to test how neural circuits function, as
'/>"/>
| Contact: Michael Bishop michael.bishop@iop.org 44-117-930-1032 Institute of Physics Source:Eurekalert |
Related biology technology :
1. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
2. CardioWest™ Artificial Heart Approved For Highest Reimbursement in CMS History : Plus Up To $53,000 New Technology Add-on Payments
3. Yongye Biotechnology International Retains CCG Investor Relations
4. William F. Prendergast Named One of the Top IP Lawyers in Nanotechnology
5. John Grisham Joins Focused Ultrasound Surgery Foundation Board, Citing Novel Technologys Potential to Help Millions of Patients
6. Yongye Biotechnology International Announces Conference Call to Discuss Second Quarter 2008 Results
7. [video] Jacques Tizabi, CEO of Universal Detection Technology Discusses Latest Purchase Order on WallSt.nets 3-Minute Press Show
8. Yongye Biotechnology International Announces Second Quarter Results
9. BeaconEquity.com Issues Trade Alerts on Biotechnology Stocks: ELN, PFE, AMGN, DNA, BIIB, GILD
10. ArunA Biomedical Announces Exclusive Worldwide Technology Licensing Agreement to Commercialize Human Embryonic Stem Cell Derived Mesenchymal Cells
11. Lixte Biotechnology Holdings Announces Filing of a New Patent Application for Cancer Therapy Based on Targeting a Biomarker by Novel Investigational Agents
| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |